Muscle atrophy

Immunis Discusses with Experts Why the Immune System is the Key to Human Healthspan

Retrieved on: 
Friday, April 5, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Health Technology, Clinical Trials, Immune system, Human, Notifiable disease, Therapy, Muscle atrophy, Multimedia, Metabolism, Sarcopenia, Facial muscles, DSM-IV codes, Cell, Inc., Vaccine

View the full release here: https://www.businesswire.com/news/home/20240405602477/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240405602477/en/
    “Aging is a manifestation of immune decline.
  • This staggering statistic emphasizes the need for interventions that restore immune function to prevent the onset of such diseases.
  • By focusing on the prevention of immune dysregulation and the maintenance of immune health, Immunis aims to empower individuals to take charge of how they age.
  • Immunis aims to ignite a conversation on the profound benefits of nurturing the immune system for a transformative impact on muscle health and ultimately, human healthspan.

Immunis Publishes Research Showing Secretomes Improve Metabolism and Muscle While Reducing Fat in Aged Models

Retrieved on: 
Tuesday, March 19, 2024
Men, Other Health, General Health, Pharmaceutical, Consumer, Infectious Diseases, Fitness & Nutrition, Biotechnology, Women, Alternative Medicine, Seniors, Vitamins, Supplements, Health, Metabolism, Adipose tissue, Obesity, Facial muscles, Connective tissue, Blood, Immunotherapy, Inc., Weight gain, Ageing, Fracture, Research, Mouse, DSM-IV codes, Aging Cell, University, Hope, Human, Muscle atrophy, Sarcopenic obesity, Therapy, Hospital, Dietary supplement

The study, published in Aging Cell, is entitled “ Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice .” The research examines the effects of Immunis’ investigational secretome on metabolism, fat and skeletal muscle in aged mouse models.

Key Points: 
  • The study, published in Aging Cell, is entitled “ Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice .” The research examines the effects of Immunis’ investigational secretome on metabolism, fat and skeletal muscle in aged mouse models.
  • As we age, our metabolic health declines and commonly manifests as obesity, muscle atrophy, and reduced physical function.
  • Dr. Drummond’s independent research in aged mouse models shows that Immunis’ immunotherapy, IMMUNA, increases whole-body lean mass and reduces fat mass, while increasing muscle fiber area.
  • Muscle quality improved such that there was an increase in muscle ‘stem’ cells, enhanced collagen turnover, more blood vessels and decreased muscle fat.

Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshot

Retrieved on: 
Monday, March 18, 2024
Surgery, Other Health, Other Science, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Technology, Fitness & Nutrition, Clinical Trials, Stem Cells, Women, Science, Biotechnology, Practice Management, Seniors, Physical Therapy, Nanotechnology, Alternative Medicine, Managed Care, Medical Supplies, Men, FDA, Health, Diabetes, Consumer, Notifiable disease, Longevity, Facial muscles, Education, Patient, Ageing, Research, Sarcopenia, DSM-IV codes, Aging Cell, Quality of life, Human, Regenerative medicine, Safety, Fix, Muscle atrophy, Dietary supplement

Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles.

Key Points: 
  • Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles.
  • In fact, Abundance360 showcases “Moonshots,” or transformative ideas, from leaders who are making excellent strides to revolutionize human healthspan.
  • Dr. Keirstead’s Moonshot aims for the incredible goal of one day treating 500M individuals with Immunis’ investigational secretome (IMMUNA) to combat age-related immune dysfunction, targeting muscle atrophy and metabolic decline.
  • Dr. Keirstead’s Moonshot with IMMUNA aligns perfectly with his “Massive Transformative Purpose” to democratize regenerative medicine and enable everyone to live healthier lives.

triLift By Lumenis Receives Medical Device License from Health Canada, Launches in Canada

Retrieved on: 
Monday, March 25, 2024
Facial muscles, Facial, DOI, Face, Eye, Patient, SAN, Gold, Aesthetics, RF, MDL, IPL, Health Canada, Eyelid, CO2, Intense, Skin, Invention, Vision, Laser, Region, Cosmetic, Physician, Muscle atrophy, Ageing, Medical imaging

SAN JOSE, Calif., March 25, 2024 /PRNewswire/ -- Lumenis Be, Ltd., a global leader in developing and commercializing energy-based solutions for the Aesthetic and Vision markets, is proud to announce that the Facial Muscle Stimulation treatment that has taken over the U.S. is now coming to Canada. triLift, the groundbreaking Dynamic Muscle Stimulation technology (DMSt™), has received a Medical Device License (MDL) from Health Canada.

Key Points: 
  • triLift, the groundbreaking Dynamic Muscle Stimulation technology (DMSt™), has received a Medical Device License (MDL) from Health Canada.
  • Finally, practitioners in Canada can go beyond the skin, to address a key cause of facial aging—the muscles.
  • triLift by Lumenis is a unique device, allowing providers to target a patient's specific need with a quick, comfortable treatment option.
  • "The clearance of triLift by Health Canada is a significant moment in the Canadian facial aesthetics market," said Lumenis Vice President & Regional President, Americas, Brad Oliver.

Springbok Analytics Receives $1.7m Phase II SBIR Grant from the NIH to Advance its Rotator Cuff Muscle Analysis Technology

Retrieved on: 
Tuesday, March 5, 2024
Data science, Bangladesh Technical Education Board, NP-hardness, SBIR, Research, Doctor of Philosophy, AI, University of Virginia, NIH, Shoulder, Pathology, FDA, Elective surgery, 3D, Surgeon, Entrepreneurship, University, Therapy, Tears, Scientific Reports, Jan Vansina, Patient, RC, Diagnosis, Machine learning, Muscle atrophy, Springbok, Atrophy, Artificial intelligence, MRI, Medical imaging

"Springbok has the potential to significantly enhance how we understand, manage, and treat RC tears and improve surgical outcomes.

Key Points: 
  • "Springbok has the potential to significantly enhance how we understand, manage, and treat RC tears and improve surgical outcomes.
  • Springbok's technology overcomes these two challenges through the use of AI and innovative analysis methods, described in recent studies in Radiology: Artificial Intelligence and Scientific Reports .
  • Leveraging its proprietary muscle analytics, Springbok's AI technology produces an enhanced RC analysis from standard MRIs that are acquired within the clinical workflow.
  • "Phase I demonstrated implementation viability of our new analysis, proving it was both valuable and practical within the clinical setting.

Confiscated Tiger Cub Brought to Oakland Zoo for Long-Term Rehabilitation and Care

Retrieved on: 
Friday, February 23, 2024
Zoo, AZA, Big Cat Rescue, Education, Medicine, Pain, Animal, Female, Injury, Surgeon, Calcium, Hope, California Department, Tiger King, Commerce, Safety, History, Nutrient, Cat, Accreditation, Knowledge, Rehabilitation, Legal case, Fracture, Muscle atrophy, Breeding, Running

OAKLAND, Calif., Feb. 23, 2024 /PRNewswire-PRWeb/ -- On Tuesday afternoon, Oakland Zoo, acting as agents for the California Department of Fish and Wildlife, assisted with rescuing an eight-month-old female tiger from a privately owned facility in the western U.S. The female tiger was found to be suffering from numerous improperly healed fractures in her bones. Oakland Zoo's Veterinary Hospital staff performed a thorough physical exam, CT scan, and bloodwork. It was determined that the patient had ten pathological fractures, leading to pain and a lack of mobility. This led to a 50% muscle atrophy in her legs. She was supplemented with nutrients and given the necessary pain medication. "I've treated over 100 cases of rescued big cats, and unfortunately, these injuries can lead to lifelong medical issues," says Dr. Ryan Sadler, Senior Veterinarian at Oakland Zoo.The Zoo's Veterinary Hospital team is working to build her calcium and muscle growth, which can take several weeks to months. Once her bones have built enough calcium, the Zoo's Veterinarians will work with surgeons to determine the next steps in her healing journey. Oakland Zoo veterinarians are cautiously optimistic, though it will take some time, that she will make a full recovery.

Key Points: 
  • Now receiving specialized care at Oakland Zoo's Veterinary Hospital, the eight-month-old tiger has a hopeful future.
  • Oakland Zoo veterinarians are cautiously optimistic, though it will take some time, that she will make a full recovery.
  • We are grateful to serve in a role that gives her hope for brighter days ahead," says Nik Dehejia, CEO of Oakland Zoo.
  • With their expertise, knowledge, and exemplary standards of care, Oakland Zoo is equipped to execute the rehabilitation this rescued female tiger needs to begin her long journey to recovery.

BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Therapy, OrbiMed, Body composition, Obesity, Incretin, Ageing, Weight loss, Venture round, Doctor of Philosophy, DSM-IV codes, Pivotal, Biology, Muscle atrophy, Investment, Pharmaceutical industry

BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.

Key Points: 
  • BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.
  • In connection with the financing, James Healy, M.D., Ph.D., managing partner at Sofinnova Investments, will join BioAge as Chairman of the Board, and Patrick Enright, managing director at Longitude Capital, will join as Board Director.
  • In preclinical studies, azelaprag doubled the weight loss achieved on incretin drugs with improvements in body composition and muscle function.
  • “We’re thrilled to partner with a top-tier syndicate of investors and pharma companies at the forefront of developing novel therapeutics for metabolic diseases,” said Kristen Fortney, Ph.D., CEO and co-founder of BioAge.

First Carbonhand prescribed to a US Veteran

Retrieved on: 
Wednesday, February 7, 2024
IBM, Glass, Family, Veterans' affairs, Facial muscles, Freedom, Patient, Veteran, Tendon, Face, Muscle atrophy, Autoimmune disease, Real estate

KISTA, Sweden, Feb. 7, 2024 /PRNewswire/ -- Mr. Lamb has inclusion body myositis (IBM), a rare autoimmune disease that primarily affects skeletal muscles with reduced muscle strength and endurance as characteristic symptoms. IBM differs from other types of autoimmune diseases with slowly progressive muscle weakness and muscle atrophy, finger flexor weakness is a central and early presenting symptom. Patients experience challenges in many areas of their lives. Gripping and holding objects as well as fine-motor activities are major parts of the challenges they face. Individuals with advanced IBM have difficulties holding utensils, gripping a glass to drink, holding a toothbrush, dressing and undressing as well as many other activities of daily living requiring grip. 

Key Points: 
  • Carbonhand is available to all US veterans through a network of sales agents covering over 80% of VA Medical Centers across the US.
  • This first prescription paves the way for other US Veterans with impaired hand function to regain hand function and become more independent.
  • I am very grateful for this opportunity and look forward to having a more active life again," says John Lamb, US Veteran.
  • "Carbonhand is fully covered by Veteran Affairs, and since its introduction in the US, we have met many veterans with different diagnoses whom can benefit from improved grip through the use of Carbonhand.

Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis

Retrieved on: 
Friday, January 26, 2024
Principal, ALS, Research, University of Tokushima, Biomedical sciences, Patient, Safety, Respiratory failure, Ministry, Neurodegenerative disease, Paralysis, Disease, MHLW, JAMA Neurology, Agonal respiration, Death, Eisai, Medication, PDMA, Muscle atrophy, NDA, Pharmaceutical industry

TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.

Key Points: 
  • TOKYO, Jan 26, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.
  • In May 2022, ultrahigh-dose mecobalamin received orphan drug designation by the Ministry of Health, Labour and Welfare (MHLW).
  • The results of JETALS were published in the peer-reviewed journal JAMA Neurology.
  • ALS is an intractable, progressive, neurodegenerative disease that results in severe muscle atrophy and weakness in the muscles due to motor neuron dysfunction.

New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA

Retrieved on: 
Wednesday, January 10, 2024
Fruit, Patient, Rosaceae, Research, Facial muscles, Associate, Delayed onset muscle soreness, BAG3, Carica, Hong Kong Baptist University, Muscular dystrophy, Myopathy, Disability studies, Prescription, HKBU, Traditional Chinese medicine, Disease, Safety, FDA, Pain, Caricaceae, Investigational New Drug, Agonal respiration, Cardiomyopathy, Paralysis, Muscle atrophy, Pharmaceutical industry

The drug has obtained the orphan drug designation from the US Food and Drug Administration (FDA), and is the first botanical drug in Hong Kong to receive this qualification.

Key Points: 
  • The drug has obtained the orphan drug designation from the US Food and Drug Administration (FDA), and is the first botanical drug in Hong Kong to receive this qualification.
  • The research team plans to submit an Investigational New Drug application to FDA in two years to conduct clinical trials.
  • Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) and Director of the Centre for Chinese Herbal Medicine Drug Development at HKBU, said: "CDD-2107 is the fruit of the integration of Chinese medicine theory and modern technology.
  • Receiving the orphan drug designation by FDA for CDD-2107 is an encouraging milestone and recognition of our team's dedication to scientific innovation."